Sun Pharma Share Price Gains Nearly 2%; Secures FDA Approval for ILUMYA in Treating Psoriatic Arthritis

On October 30, 2026, Sun Pharmaceutical Industries Limited announced that the U.S. Food and Drug Administration (FDA) has approved its supplemental Biologics License Application for ILUMYA, as per the exchange filings.  

This approval allows the medication to be used for treating active psoriatic arthritis in adults, expanding its therapeutic applications beyond its initial approval for moderate-to-severe plaque psoriasis in 2018. 

FDA Approval for ILUMYA 

The FDA's approval marks a key development for ILUMYA, an IL-23 inhibitor administered by healthcare professionals. Initially approved in 2018 for moderate-to-severe plaque psoriasis, ILUMYA can now be used for active psoriatic arthritis in adults.  

This expands its role in addressing conditions affecting approximately 24 lakh Americans, who suffer from joint swelling and potential damage due to psoriatic arthritis. 

Clinical Trials and Safety 

The FDA's decision was supported by the results of Phase 3 INSPIRE-1 and INSPIRE-2 clinical trials. These trials were randomized, double-blind, and placebo-controlled, evaluating the drug's safety and efficacy over 52 weeks.  

Efficacy and safety assessments were made after just 2 doses at week 24, with no new safety signals observed, aligning with the established safety profile of ILUMYA. 

Read More: Coforge Share Price in Focus; Introduces Autonomous Software Factory for AI Development! 

Patient Safety and Administration 

ILUMYA is designed to selectively inhibit the p19 subunit of interleukin-23. It is crucial for patients to be evaluated for tuberculosis before starting treatment, as active tuberculosis is a contraindication. Patients should avoid live vaccines.  

Common adverse reactions include upper respiratory tract infections and COVID-19, while serious allergic reactions require immediate discontinuation. 

Global Presence and Corporate Overview 

ILUMYA is approved for plaque psoriasis in several countries, including India, Australia, Canada, China, Japan, and Europe, where it is marketed as ILUMETRI by Almirall.  

Sun Pharma, the world's leading specialty generics company, operates across 6 continents with a diverse workforce from over 50 nations. Its innovative medicines portfolio contributes approximately 20% of total sales. 

Sun Pharmaceutical Industries Share Price Performance 

As of October 30, 2026, at 9:57 AM, Sun Pharmaceutical Industries share price on NSE was trading at ₹1,795.70, up by 1.97% from the previous closing price. 

Conclusion 

Sun Pharma's ILUMYA has received FDA approval for treating active psoriatic arthritis in adults, supported by Phase 3 clinical trials. The medication, already approved for plaque psoriasis, expands its therapeutic use, benefiting patients requiring healthcare provider-administered treatments. 

Disclaimer: This blog has been written exclusively for educational purposes. The securities or companies mentioned are only examples and not recommendations. This does not constitute a personal recommendation or investment advice. It does not aim to influence any individual or entity to make investment decisions. Recipients should conduct their own research and assessments to form an independent opinion about investment decisions. 

Investments in the securities market are subject to market risks, read all the related documents carefully before investing.